In an industry first, Bupa, the leading international healthcare group, has announced plans to improve the quality of its cancer cover by no longer selling corporate health insurance schemes which feature overall cost or time limits for cancer treatment.
Cancer treatment costs increased sharply in 2005 and 2006 due to the introduction of new drugs. In response to the concerns this caused about rising costs, the health insurance market developed financial benefit caps and time limits to restrict financial exposure for client businesses.
However, experience has shown that these limits mean that patients who claim on their policies can be left vulnerable at critical points in their treatment.
Once employees reach their benefit ceiling they face the possibility of having to change their treatment mid-stream. The varying cost of cancer drugs also makes it very difficult for patients to make informed choices about their treatment path, and its likely cost, at the point of diagnosis.
Dr Natalie-Jane Macdonald, managing director, Bupa Health and Wellbeing explained: "We work closely with our clients to help them to provide their employees with the best quality healthcare at a sustainable affordable cost, and this remains a priority for us. We have developed better, fairer ways of controlling healthcare costs without compromising the experience and outcomes of patients at a difficult time in their lives."
In 2010 Bupa spent 18m pounds Sterling on drugs that are not widely available elsewhere and it routinely funds cancer treatments that are approved by the European Medicines Agency. Bupa also makes prompt decisions to pay for experimental drugs when clinically appropriate.
Breakthrough imaging method enhances precision in prostate cancer treatment